MRK vs RSPE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Sell and RSPE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 2 FA rating(s) are green while.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 4 TA indicator(s) are bullish.
- MRK’s TA Score: 4 bullish, 3 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а -6.42% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -4.55%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was +2.00%.
Reported Earning Dates
MRK is expected to report earnings on Feb 04, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (-4.55% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
MRK | ||
|---|---|---|
OUTLOOK RATING 1..100 | 51 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 41 | |
SMR RATING 1..100 | 28 | |
PRICE GROWTH RATING 1..100 | 64 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| MRK | RSPE | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 66% | N/A |
| Stochastic ODDS (%) | 3 days ago 65% | 3 days ago 69% |
| Momentum ODDS (%) | N/A | 3 days ago 89% |
| MACD ODDS (%) | 3 days ago 43% | 3 days ago 77% |
| TrendWeek ODDS (%) | 3 days ago 49% | 3 days ago 73% |
| TrendMonth ODDS (%) | 3 days ago 43% | 3 days ago 74% |
| Advances ODDS (%) | 10 days ago 48% | 7 days ago 75% |
| Declines ODDS (%) | 3 days ago 49% | 3 days ago 76% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 85% |
| Aroon ODDS (%) | 3 days ago 44% | 3 days ago 75% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| TRWIX | 21.03 | -0.04 | -0.19% |
| Transamerica International Equity I2 | |||
| MVTIX | 11.92 | -0.08 | -0.67% |
| Transamerica Mid Cap Value Opps I | |||
| HNDDX | 73.75 | -0.80 | -1.07% |
| Horizon Equity Premium Income Investor | |||
| QDISX | 17.87 | -0.22 | -1.22% |
| Fisher IIG Stock for Ret Plns | |||
| PNOTX | 23.23 | -0.32 | -1.36% |
| Putnam Sustainable Future R6 | |||
MRK and
Correlation & Price change
A.I.dvisor tells us that MRK and AZN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRK and AZN's prices will move in lockstep.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | -2.08% | ||
| AZN - MRK | 30% Poorly correlated | -2.78% | ||
| GSK - MRK | 23% Poorly correlated | -1.91% | ||
| NVS - MRK | 22% Poorly correlated | -0.33% | ||
| BIIB - MRK | 21% Poorly correlated | -2.97% | ||
| AMGN - MRK | 21% Poorly correlated | -4.16% | ||
More | ||||
RSPE and
Correlation & Price change
A.I.dvisor tells us that RSPE and MRK have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RSPE and MRK's prices will move in lockstep.
| Ticker / NAME | Correlation To RSPE | 1D Price Change % | ||
|---|---|---|---|---|
| RSPE | 100% | -0.82% | ||
| MRK - RSPE | 20% Poorly correlated | -2.08% | ||
| NSC - RSPE | 16% Poorly correlated | -1.32% | ||
| TJX - RSPE | 15% Poorly correlated | +0.05% | ||
| VTR - RSPE | 14% Poorly correlated | +0.16% | ||
| WELL - RSPE | 14% Poorly correlated | +1.19% | ||
More | ||||